Session » Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

Date: Saturday, November 16, 2024

Time: 3:00PM-4:30PM

Meeting: ACR Convergence 2024

3:00PM-4:30PM: Abstract Number: 0876

C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases

3:00PM-4:30PM: Abstract Number: 0874

Defining a Protective Role for Mucosal-associated Invariant T (MAIT) Cells in Spontaneous Cutaneous Lupus Erythematosus

3:00PM-4:30PM: Abstract Number: 0835

Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)

3:00PM-4:30PM: Abstract Number: 0873

Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)

3:00PM-4:30PM: Abstract Number: 0836

NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses

3:00PM-4:30PM: Abstract Number: 0875

Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].